BIOTON S.A. (PL:BIO)
:BIO
Top Page
BIOTON S.A.
(BIO)
Select Model
Select Model
Rating:51Neutral
Price Target:
zł4.00
▼(-1.72% Downside)
Action:N/ADate:09/14/25
BIOTON S.A.'s overall score of 51 reflects a cautious outlook driven primarily by mixed financial performance, with strong cash flow and balance sheet stability offset by profitability challenges. Valuation concerns due to a negative P/E ratio further weigh on the score, while limited technical data provides a neutral impact.
BIOTON S.A. (BIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
zł369.22M
Dividend YieldN/A
Average Volume (3M)33.62K
Price to Earnings (P/E)97.7
Beta (1Y)0.19
Revenue Growth42.31%
EPS Growth-51.82%
CountryPL
Employees361
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.02
Shares Outstanding85,864,200
10 Day Avg. Volume22,695
30 Day Avg. Volume33,619
Financial Highlights & Ratios
PEG Ratio-0.80
Price to Book (P/B)0.56
Price to Sales (P/S)1.17
P/FCF Ratio145.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.14
Revenue Forecast (FY)zł266.00M
BIOTON S.A. Business Overview & Revenue Model
Company Description
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceuticals, pharmaceutical preparations, pharmaceutical substances, medications, and other pharmaceutical products in Poland, China, Thailand, Vietnam, Libya, Ar...
How the Company Makes Money
BIOTON generates revenue through several key streams, primarily from the sale of its insulin products and biosimilars, which are marketed in various countries. The company has established partnerships with international pharmaceutical companies, e...
BIOTON S.A. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
65
Positive
Cash Flow
70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 282.52M | 207.76M | 181.64M | 233.16M | 163.03M |
| Gross Profit | 91.80M | 64.84M | 72.85M | 95.75M | 76.32M |
| EBITDA | 52.89M | 32.57M | 31.26M | 58.56M | 45.09M |
| Net Income | 3.39M | -15.66M | 2.27M | 1.42M | 2.88M |
Balance Sheet | |||||
| Total Assets | 764.56M | 794.14M | 822.22M | 810.33M | 865.19M |
| Cash, Cash Equivalents and Short-Term Investments | 8.28M | 6.96M | 3.88M | 9.34M | 8.86M |
| Total Debt | 57.16M | 56.57M | 68.69M | 76.39M | 110.08M |
| Total Liabilities | 170.59M | 203.59M | 215.87M | 204.27M | 242.45M |
| Stockholders Equity | 593.97M | 590.55M | 606.36M | 606.06M | 604.51M |
Cash Flow | |||||
| Free Cash Flow | 2.28M | 24.72M | -4.54M | 26.50M | -7.37M |
| Operating Cash Flow | 15.34M | 36.33M | 39.63M | 56.08M | 5.52M |
| Investing Cash Flow | -13.01M | -11.61M | -36.95M | -29.10M | -4.28M |
| Financing Cash Flow | -1.01M | -21.64M | -8.13M | -26.50M | -14.62M |
BIOTON S.A. Technical Analysis
Positive
4.07
Price Trends
4.14
Positive
4.05
Positive
4.17
Positive
Market Momentum
0.04
Negative
58.91
Neutral
86.27
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:BIO, the sentiment is Positive. The current price of 4.07 is below the 20-day moving average (MA) of 4.19, below the 50-day MA of 4.14, and below the 200-day MA of 4.17, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 58.91 is Neutral, neither overbought nor oversold. The STOCH value of 86.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PL:BIO.
BIOTON S.A. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | zł138.67M | -3.23 | -59.73% | ― | -74.16% | -192.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | zł369.22M | 97.68 | -1.76% | ― | 42.31% | -51.82% | |
51 Neutral | zł550.66M | -187.28 | -1.25% | ― | 14.10% | -99.00% | |
44 Neutral | zł529.45M | -6.19 | -110.42% | ― | 15.45% | -25.81% | |
42 Neutral | zł448.71M | -4.87 | -109.96% | ― | -40.45% | 27.53% |
* Healthcare Sector Average
PL:BIO
BIOTON S.A.
4.30
0.70
19.44%
PL:RVU
Ryvu Therapeutics SA
22.90
0.30
1.33%
PL:SVE
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.
3.68
-0.64
-14.81%
PL:CTX
Captor Therapeutics SA
80.80
46.30
134.20%
PL:SLV
Selvita SA
30.00
-3.80
-11.24%
PL:MAB
Mabion SA
8.58
-0.70
-7.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.